semaglutide and high bilirubin in MASLD Patients: Improved Survival Liver Outcomes #like #medical #education #education #med

In this Food Business News CloseUp, we explore how GLP-1s are reducing food spending, shifting category demand and forcing brands to rethink product strategy

Compounders were expected to cease production of tirzepatide by March 2025 and semaglutide by May 2025, yet both remain active in the market

Fibroids are unlikely to become cancerous, but it's best to get unexplained tumors checked out.

Achieve your health goals with specialized plans and support designed just for you.

The CEO of the Alliance for Pharmacy Compounding unpacks how the ruling affects telehealth providers and what it could signal for future GLP-1 entrants and market dynamics:

Danielle Brightman, clinical director of Numan, argues that a poorly regulated peptide market will set back progress in obesity medication by years and put people in danger.